TY - JOUR
T1 - Advanced MR Techniques for Preoperative Glioma Characterization: Part 1
AU - Hirschler, Lydiane
AU - Sollmann, Nico
AU - Schmitz‐abecassis, Bárbara
AU - Pinto, Joana
AU - Arzanforoosh, Fatemehsadat
AU - Barkhof, Frederik
AU - Booth, Thomas
AU - Calvo‐imirizaldu, Marta
AU - Cassia, Guilherme
AU - Chmelik, Marek
AU - Clement, Patricia
AU - Ercan, Ece
AU - Fernández‐seara, Maria A.
AU - Furtner, Julia
AU - Fuster‐garcia, Elies
AU - Grech‐sollars, Matthew
AU - Guven, Nazmiye Tugay
AU - Hatay, Gokce Hale
AU - Karami, Golestan
AU - Keil, Vera C.
AU - Kim, Mina
AU - Koekkoek, Johan A. F.
AU - Kukran, Simran
AU - Mancini, Laura
AU - Nechifor, Ruben Emanuel
AU - Özcan, Alpay
AU - Ozturk‐isik, Esin
AU - Piskin, Senol
AU - Schmainda, Kathleen
AU - Svensson, Siri F.
AU - Tseng, Chih‐hsien
AU - Unnikrishnan, Saritha
AU - Vos, Frans
AU - Warnert, Esther
AU - Zhao, Moss Y.
AU - Jancalek, Radim
AU - Nunes, Teresa
AU - Emblem, Kyrre E.
AU - Smits, Marion
AU - Petr, Jan
AU - Hangel, Gilbert
N1 - Funding Information:
We want to thank Rosa Ayesa Arriola, Martin Barak, Paula Croal, Philip De Witt Hamer, Vasileios K. Katsaros, Mary Pelechrini, Zahra Shams, Danai‐Eleni Stefanou, Ioannis John Toliopoulos, and Hana Valekova for their assistance with earlier versions of this manuscript. This review was funded by grants from the following agencies: Dutch Research Council (NWO), Veni project numbers 91619121 and 16862, VICI project number 016.160.351; Wellcome Trust 2022‐24, 203148/A/16/Z; Spanish Ministry of Science and Innovation (grant: PI18/00084), Spanish State Research Agency, Subprogram for Knowledge Generation (PROGRESS, No PID2021‐127110OA‐I00). Austrian Science Funds (FWF) projects KLI 646 and 1089; a 2021 Comprehensive Cancer Center grant of the Medical University of Vienna; The Turkish Directorate of Strategy and Budget under the TAM Project number 2007K12‐873; INTER‐EXCELLENCE, subprogram INTER‐COST of the Ministry of Education, Youth and Sports CZ, Grant No. LTC20027; TUBITAK 1003 grant 216S432; European Research Agency, Marie Sklodowska Curie Fellowship, Horizon 2020; NIH/NCI U01 CA176110, NIH/NCI R01 CA264992, NIH/NCI CA255123; HollandPTC‐Varian grant ID: 2018017; European Union's Horizon 2020 Programme: ERC Grant Agreement No. 758657‐ImPRESS; South‐Eastern Norway Regional Health Authority Grant Agreements No. 2016102, 2017073, 2013069; the Norwegian Cancer Society and the Research Council of Norway FRIPRO Grant Agreements No. 261984, 303249; the MS Society of the United Kingdom (grant: 125); and the American Heart Association (Grant: 826254). This publication is part of the COST Action CA18206 Glioma MR Imaging 2.0, supported by COST (European Cooperation in Science and Technology), www.cost.eu www.glimr.eu .
Funding Information:
We want to thank Rosa Ayesa Arriola, Martin Barak, Paula Croal, Philip De Witt Hamer, Vasileios K. Katsaros, Mary Pelechrini, Zahra Shams, Danai-Eleni Stefanou, Ioannis John Toliopoulos, and Hana Valekova for their assistance with earlier versions of this manuscript. This review was funded by grants from the following agencies: Dutch Research Council (NWO), Veni project numbers 91619121 and 16862, VICI project number 016.160.351; Wellcome Trust 2022-24, 203148/A/16/Z; Spanish Ministry of Science and Innovation (grant: PI18/00084), Spanish State Research Agency, Subprogram for Knowledge Generation (PROGRESS, No PID2021-127110OA-I00). Austrian Science Funds (FWF) projects KLI 646 and 1089; a 2021 Comprehensive Cancer Center grant of the Medical University of Vienna; The Turkish Directorate of Strategy and Budget under the TAM Project number 2007K12-873; INTER-EXCELLENCE, subprogram INTER-COST of the Ministry of Education, Youth and Sports CZ, Grant No. LTC20027; TUBITAK 1003 grant 216S432; European Research Agency, Marie Sklodowska Curie Fellowship, Horizon 2020; NIH/NCI U01 CA176110, NIH/NCI R01 CA264992, NIH/NCI CA255123; HollandPTC-Varian grant ID: 2018017; European Union's Horizon 2020 Programme: ERC Grant Agreement No. 758657-ImPRESS; South-Eastern Norway Regional Health Authority Grant Agreements No. 2016102, 2017073, 2013069; the Norwegian Cancer Society and the Research Council of Norway FRIPRO Grant Agreements No. 261984, 303249; the MS Society of the United Kingdom (grant: 125); and the American Heart Association (Grant: 826254). This publication is part of the COST Action CA18206 Glioma MR Imaging 2.0, supported by COST (European Cooperation in Science and Technology), www.cost.eu www.glimr.eu.
Publisher Copyright:
© 2023 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.
PY - 2023/6
Y1 - 2023/6
N2 - Preoperative clinical magnetic resonance imaging (MRI) protocols for gliomas, brain tumors with dismal outcomes due to their infiltrative properties, still rely on conventional structural MRI, which does not deliver information on tumor genotype and is limited in the delineation of diffuse gliomas. The GliMR COST action wants to raise awareness about the state of the art of advanced MRI techniques in gliomas and their possible clinical translation or lack thereof. This review describes current methods, limits, and applications of advanced MRI for the preoperative assessment of glioma, summarizing the level of clinical validation of different techniques. In this first part, we discuss dynamic susceptibility contrast and dynamic contrast-enhanced MRI, arterial spin labeling, diffusion-weighted MRI, vessel imaging, and magnetic resonance fingerprinting. The second part of this review addresses magnetic resonance spectroscopy, chemical exchange saturation transfer, susceptibility-weighted imaging, MRI-PET, MR elastography, and MR-based radiomics applications.Evidence Level: 3Technical Efficacy: Stage 2
AB - Preoperative clinical magnetic resonance imaging (MRI) protocols for gliomas, brain tumors with dismal outcomes due to their infiltrative properties, still rely on conventional structural MRI, which does not deliver information on tumor genotype and is limited in the delineation of diffuse gliomas. The GliMR COST action wants to raise awareness about the state of the art of advanced MRI techniques in gliomas and their possible clinical translation or lack thereof. This review describes current methods, limits, and applications of advanced MRI for the preoperative assessment of glioma, summarizing the level of clinical validation of different techniques. In this first part, we discuss dynamic susceptibility contrast and dynamic contrast-enhanced MRI, arterial spin labeling, diffusion-weighted MRI, vessel imaging, and magnetic resonance fingerprinting. The second part of this review addresses magnetic resonance spectroscopy, chemical exchange saturation transfer, susceptibility-weighted imaging, MRI-PET, MR elastography, and MR-based radiomics applications.Evidence Level: 3Technical Efficacy: Stage 2
UR - http://www.scopus.com/inward/record.url?scp=85149469575&partnerID=8YFLogxK
U2 - 10.1002/jmri.28662
DO - 10.1002/jmri.28662
M3 - Review article
SN - 1522-2586
VL - 57
SP - 1655
EP - 1675
JO - Journal of Magnetic Resonance Imaging
JF - Journal of Magnetic Resonance Imaging
IS - 6
ER -